WISP-3 drives LUAD metastasis by suppressing miR-5004-5p to upregulate MMP-12

  • Biochem Pharmacol. 2026 Jun 25;251(Pt 2):118189. doi: 10.1016/j.bcp.2026.118189.
Chia-Chia Chao  1 Chiang-Wen Lee  2 Syuan-Ling Lin  3 Yu-Chen Chen  4 Ching-Yuan Cheng  5 En-Ming Chang  6 Chih-Hsin Tang  7 Chih-Yang Lin  8
Affiliations
  • 1. Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City, Taiwan; Center for Health Research and Innovation, Fu Jen Catholic University, New Taipei City, Taiwan.
  • 2. Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan; Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi, Taiwan; Chronic Diseases and Health Promotion Research Center and Center for Smart Healthcare Education and Drug Research and Development, Chang Gung University of Science and Technology, Chiayi, Taiwan; Department of Safety Health and Environmental Engineering, Ming Chi University of Technology, New Taipei City, Taiwan.
  • 3. Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • 4. Translational Medicine Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • 5. Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • 6. Department of Respiratory Care, Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan.
  • 7. Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan; Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan; Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
  • 8. Translational Medicine Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan. Electronic address: [email protected].
Abstract

Lung adenocarcinoma (LUAD) is characterized by a high propensity for metastasis and poor clinical outcomes. Although members of the cellular communication network (CCN) family exhibit context-dependent roles in tumor progression, the function of WNT1-inducible signaling pathway protein 3 (WISP-3), also known as CCN6, in LUAD remains incompletely understood. In this study, we demonstrate that WISP-3 is significantly upregulated in LUAD tissues and is associated with unfavorable patient survival. Functional assays revealed that WISP-3 enhances cell migration and wound healing capacity in LUAD cells. Mechanistically, WISP-3 activates proto-oncogene tyrosine-protein kinase Src (Src) and focal adhesion kinase (FAK) signaling, leading to suppression of microRNA-5004-5p (miR-5004-5p). We further show that miR-5004-5p negatively regulated matrix metalloproteinase-12 (MMP-12) expression through interaction with the 3' untranslated region (3'UTR) of MMP-12 mRNA. Suppression of miR-5004-5p by WISP-3 was accompanied by increased MMP-12 expression. Notably, MMP-12 was elevated in LUAD tissues and correlates with poor patient prognosis, supporting its role as a clinically relevant downstream effector. Restoration of miR-5004-5p or inhibition of Src/FAK signaling significantly attenuated WISP-3-induced migratory and MMP-12 expression. Collectively, our findings identify a WISP-3-driven signaling cascade that promotes LUAD metastasis through miR-5004-5p suppression and subsequent MMP-12 upregulation. This study provides new insights into the context-specific function of WISP-3 and highlights the WISP-3/Src/FAK/miR-5004-5p/MMP-12 axis as a potential therapeutic target in LUAD.

Keywords
Lung adenocarcinoma; MMP-12; Metastasis; WISP-3; hsa-miR-5004-5p.
Products